Anti-pro-N-cadherin antibodies and methods of treating pathological fibrotic conditions and tumor cells
AssigneeDuke University
InventorsPaul Ferrell, Salvatore Pizzo, Robin Bachelder
Life of this patent
Estimating the term…
Abstract
Humanized antibody to a pathologically mislocated form of N-cadherin detects and eliminates cells that express the protein extracellularly. These cells are found in fibrotic conditions within heart, lung, and liver, as well as kidney, skin, and other organs effected by fibrosis. The antibody does not affect cells with normal, subcellular location of the protein.
Claims14
A humanized antibody which specifically binds to pro-N-cadherin in its pro-domain, said humanized antibody comprising:
- framework portions of a human antibody;
- and
- six complementarity determining regions (CDRs) of a mouse antibody, wherein the CDRs are SEQ ID NO:
- 22-27 or SEQ ID NO:
- 28-33.
A method of treating a human with a pathological fibrotic condition to reduce number of pathological fibrotic cells in the human, said method comprising:
- administering to the human a humanized antibody that binds to pro-N-cadherin in its pro-domain, whereby number of pathological fibrotic cells is reduced;
- wherein the humanized antibody comprises framework portions from a human antibody;
- and six complementarity determining regions (CDRs) from a mouse antibody, wherein the CDRs are SEQ ID NO:
- 22-27 or SEQ ID NO:
- 28-33.
A method of treating a human with a tumor condition to reduce number of tumor cells in the human, said method comprising:
- administering to the human a humanized antibody that binds to pro-N-cadherin in its pro-domain, whereby number of tumor cells in the human is reduced;
- wherein the humanized antibody comprises framework portions from a human antibody and six complementarity determining regions (CDRs) from a mouse antibody;
- and wherein the CDRs are SEQ ID NO:
- 22-27 or SEQ ID NO:
- 28-33.
A chimeric antibody which specifically binds to pro-N-cadherin in its pro-domain, said chimeric antibody comprising:
- framework portions from a non-murine antibody;
- and six complementarity determining regions (CDRs) from a mouse antibody, wherein the CDRs are SEQ ID NO:
- 22-27 or SEQ ID NO:
- 28-33.
Dependencies are inferred from the claim text.